Study Suggests Spread Pricing Ban on PBMs Alone May Have Little Impact
Although PBMs are taking increasing heat for spread pricing — or charging payers more for a drug than pharmacies are reimbursed — they aren’t the only players in the drug supply chain that engage in the practice, a new study points out. And one of the study’s authors says its findings suggest that patients may be better off if generic drugs are simply removed from insurance coverage entirely.
The study, published in JAMA Health Forum on Oct. 20, examined data associated with 45 high-utilization Medicare Part D-covered generic drugs.
© 2025 MMIT
Related Posts
![stocking-pharmacy-shelves](https://www.mmitnetwork.com/wp-content/uploads/2023/10/WordPress-Featured-Image_AdobeStock_217828923.jpg)
October
12
Large-Employer Groups Dispute PCMA Claim That Some Firms Prefer Spread Pricing
READ MORE![bills-and-pills](https://www.mmitnetwork.com/wp-content/uploads/2022/05/bills-and-pills.png)
September
28
PhRMA-Funded Report Finds PBMs Increasingly Derive Profits from Fees, Specialty
READ MORE![pharmacists](https://www.mmitnetwork.com/wp-content/uploads/2023/09/WordPress-Featured-Image_AdobeStock_168113446.jpg)
September
14